Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
11/13/24 | Curium Pharma | Lu-177-PSMA-I&T for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
11/11/24 | AbbVie (ABBV) | Emraclidine for Schizophrenia | Subscribers Only | Subscribers Only | Subscribers Only |
11/8/24 | Paratek | Nuzyra for Non-Tuberculous Mycobacteria (NTM) | Subscribers Only | Subscribers Only | Subscribers Only |
11/1/24 | Novo Nordisk (NVO) | Semaglutide (NASH) for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
10/31/24 | Lexicon Pharmaceuticals (LXRX) | Inpefa for Diabetes Mellitus, Type I | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/16/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/24/2024 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
10/26/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
10/30/2024 | Subscribers Only | Subscribers Only | Progress Update - Development Review |